Sanofi | SNY - Cost Of Sales




Sanofi reported EUR4.08B in Cost of Sales for its fiscal quarter ending in September of 2024.

Cost Of Sales Change Date
AbbVie USD 4.4B 184M Dec/2024
Amgen USD 3.11B 198M Dec/2024
AstraZeneca USD 2.72B 263M Dec/2024
Bristol-Myers Squibb USD 4.81B 1.86B Dec/2024
Canopy Growth CAD 41.15M 2.03M Sep/2024
Corcept Therapeutics USD 2.87M 343K Sep/2024
Drreddys Laboratories INR 32.39B 2.01B Sep/2024
Eli Lilly USD 2.4B 233M Dec/2024
Galapagos EUR 112.93M 112.91M Dec/2024
Genmab DKK 337M 64M Dec/2024
GlaxoSmithKline GBP 2.56B 162M Dec/2024
Glaxosmithkline GBP 2.33B 271M Sep/2024
Indivior 59M 7M Sep/2024
J&J USD 6.94B 20M Dec/2024
Merck USD 3.83B 579M Dec/2024
Novartis USD 3.32B 90M Dec/2024
Novartis USD 3.24B 72M Sep/2024
Pacira USD 168.57M 122.38M Sep/2024
Perrigo USD 683.1M 12.3M Sep/2024
Pfizer USD 5.74B 480M Dec/2024
Prestige Brands USD 290.32M 6.53M Dec/2024
Roche Holding CHF 4.13B 393.5M Dec/2024
Sanofi EUR 4.08B 675M Sep/2024
Sanofi EUR 4.08B 675M Sep/2024
Supernus Pharmaceuticals USD 17.58M 333K Sep/2024
UCB EUR 425.5M 479.5M Jun/2024
Zoetis USD 707M 6M Dec/2024